Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Sylvia De Brakeleer"'
Autor:
Sofie Joris, Philippe Giron, Catharina Olsen, Sara Seneca, Alexander Gheldof, Shula Staessens, Rajendra Bahadur Shahi, Sylvia De Brakeleer, Erik Teugels, Jacques De Grève, Frederik J. Hes
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background Among the 10% of pancreatic cancers that occur in a familial context, around a third carry a pathogenic variant in a cancer predisposition gene. Genetic studies of pancreatic cancer predisposition are limited by high mortality rat
Externí odkaz:
https://doaj.org/article/0e890e7144ad45c5a4373146724f97bc
Autor:
Rajendra Bahadur Shahi, Sylvia De Brakeleer, Ben Caljon, Ingrid Pauwels, Maryse Bonduelle, Sofie Joris, Christel Fontaine, Marian Vanhoeij, Sonia Van Dooren, Erik Teugels, Jacques De Grève
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-11 (2019)
Abstract Background In the majority of familial breast cancer (BC) families, the etiology of the disease remains unresolved. To identify missing BC heritability resulting from relatively rare variants (minor allele frequency ≤ 1%), we have performe
Externí odkaz:
https://doaj.org/article/846510970de24dd1a99dcd1f16be8ccb
Autor:
Erik Teugels, Sylvia De Brakeleer
Publikováno v:
npj Breast Cancer, Vol 3, Iss 1, Pp 1-6 (2017)
Abstract While environmental factors can greatly increase cancer risk, it is clear that an individual’s genetic constitution has strong impact on tumor formation. Hereby we present an alternative cancer predisposition model built on the assumption
Externí odkaz:
https://doaj.org/article/4b9f495cbca340e2a7afda3b6b1a8835
Autor:
Christel Fontaine, Sylvia De Brakeleer, Erik Teugels, Vincent Renard, Heidi Van den Bulk, Peter Vuylsteke, Philippe Glorieux, Catherine Dopchie, Sofie Joris, Lore Decoster, Ahmad Awada, Kevin Punie, Hans Wildiers, Jacques De Grève
BackgroundBSMO 2014-01 is a published prospective phase 2 study investigating neoadjuvant weekly paclitaxel and carboplatin, followed by epirubicin and cyclophosphamide in 63 patients with triple-negative breast cancer. Pathological complete response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8bb4dc9f745c7957281f52b0188ef4dc
https://doi.org/10.21203/rs.3.rs-1584056/v1
https://doi.org/10.21203/rs.3.rs-1584056/v1
Autor:
Rajendra Bahadur Shahi, Hugo Vandenplas, Carolien Eggermont, Philippe Giron, Jacques De Greve, Erik Teugels, Bram Boeckx, Diether Lambrechts, Sylvia De Brakeleer, Alfiah Noor, Amir Noeparast
Publikováno v:
Oncogene
Two out of 41 non-small cell lung cancer patients enrolled in a clinical study were found with a somatic CRAF mutation in their tumor, namely CRAFP261A and CRAFP207S. To our knowledge, both mutations are novel in lung cancer and CRAFP261A has not bee
Autor:
Erik Teugels, Sonia Van Dooren, Marian Vanhoeij, Christel Fontaine, Ingrid Pauwels, Maryse Bonduelle, Ben Caljon, Rajendra Bahadur Shahi, Sylvia De Brakeleer, Jacques De Greve, Sofie Joris
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-11 (2019)
BMC Cancer
BMC Cancer
Background In the majority of familial breast cancer (BC) families, the etiology of the disease remains unresolved. To identify missing BC heritability resulting from relatively rare variants (minor allele frequency ≤ 1%), we have performed whole e
Autor:
Amir Noeparast, Jacques De Greve, Carolien Eggermont, Ulrike De Ridder, Erik Teugels, Philippe Giron, Sylvia De Brakeleer
Publikováno v:
Oncotarget
A large fraction of somatic driver BRAF mutations in lung cancer are non-V600 and impaired-kinase. Non-V600 BRAF mutations predict sensitivity to combination of a type I RAF inhibitor, Dabrafenib, and a MEK inhibitor, Trametinib. Singly, Dabrafenib o
Autor:
Diether Lambrechts, Guy Berchem, Peter Vuylsteke, Sebahat Ocak, Marc Lambrechts, Sylvia De Brakeleer, Daniella Galdermans, Jacques De Greve, Lynn Decoster, Erik Teugels, Bram Boeckx, Lore Decoster, Thomas Van Brussel, Koen Deschepper, Patrick Alexander, Piet Vercauter, Rajendra Bahadur Shahi, Dominiek Smeets, Nadia Cappoen
Publikováno v:
International journal of cancer, Vol. 146, no. 11, p. 3207-3218 (2020)
Lung cancer is the number one cause of cancer-related death worldwide with cigarette smoking as its major risk factor. Although the incidence of lung cancer in never smokers is rising, this subgroup of patients is underrepresented in genomic studies
Autor:
Erik Teugels, Jacques De Greve, Sylvia De Brakeleer, Lore Decoster, Amir Noeparast, Gil Verschelden, Philippe Giron
Publikováno v:
Oncotarget
// Amir Noeparast 1 , Erik Teugels 1 , Philippe Giron 1 , Gil Verschelden 1 , Sylvia De Brakeleer 1 , Lore Decoster 1 , Jacques De Greve 1 1 Laboratory of Molecular Oncology and Department of Medical Oncology, Oncologisch Centrum, UZ Brussel, Vrije U
e23197 Background: During the Belgian FIELT II clinical study, two non-small cell lung cancers among 41 were found to harbor a CRAF mutation. One of these mutations (P207S) was previously found in fibrosarcoma and characterized as not activating the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::847c808838b738a41e5f0c5f2af9a4a1
https://biblio.vub.ac.be/vubir/a-lung-cancerderived-craf-mutation-to-activate-erk-pathway-and-to-predict-sensitivity-to-ly3009120-and-trametinib(a7e5f54f-901f-45fc-84ea-595efa6de89e).html
https://biblio.vub.ac.be/vubir/a-lung-cancerderived-craf-mutation-to-activate-erk-pathway-and-to-predict-sensitivity-to-ly3009120-and-trametinib(a7e5f54f-901f-45fc-84ea-595efa6de89e).html